Epidemiological trends of HIV-1 infection in blood donors from Catalonia, Spain (2005-2014)
Por:
Bes, M, Piron, M, Casamitjana, N, Gregori, J, Esteban, JI, Ribera, E, Quer, J, Puig, L, Sauleda, S
Publicada:
1 sep 2017
Resumen:
BACKGROUNDHuman immunodeficiency virus 1 (HIV-1) subtype B is predominant in Spain. However, the recent arrival of immigrant populations has increased the prevalence of non-B subtypes and circulating recombinant forms. The objective of this study was to determine the prevalence of HIV-1 subtypes and transmitted drug-resistance mutations in blood donors from the Catalonian region (northeastern Spain).
STUDY DESIGN AND METHODSHIV-1-positive blood donors identified in Catalonia from 2005 to 2014 were included. Demographic variables and risk factors for HIV-1 acquisition were recorded. HIV-1 subtyping was carried out by HIV-1 DNA polymerase region sequencing, and phylogenetic analyses were performed using the neighbor-joining method.
RESULTSDuring the study period, 2.8 million blood donations were screened, and 214 HIV-1-positive donors were identified, yielding an overall prevalence of 7.7 per 100,000 donations (89% men; mean age, 3410 years). Most HIV-1-positive donors were native to Spain (81%), and 61% were regular blood donors. When risk factors were known, 62% reportedly were men who had sex with men. HIV-1 subtyping was possible in 176 HIV-1-positive individuals: 143 (81%) had HIV-1 subtype B, and 33 (19%) had non-B subtypes. Most HIV-1 non-B subtypes were circulating recombinant forms (n=20; 61%). Factors associated with HIV-1 subtype B were male sex (p=0.007) and men who had sex with men (p<0.001). The overall prevalence of transmitted drug-resistance mutations was 14%.
CONCLUSIONNon-B subtypes, circulating recombinant forms, and transmitted drug-resistance mutation sequences circulate among HIV-1-positive blood donors in Catalonia. Continuous local epidemiological surveillance is required to implement optimal prevention strategies for controlling transfusion-transmitted HIV and to improve health policies regarding HIV infection.
Filiaciones:
Bes, M:
Serv Catala Salut, Banc Sang & Teixits, Transfus Safety Lab, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Piron, M:
Serv Catala Salut, Banc Sang & Teixits, Transfus Safety Lab, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Casamitjana, N:
Serv Catala Salut, Banc Sang & Teixits, Transfus Safety Lab, Barcelona, Spain
Gregori, J:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
VHIR HUVH, Liver Unit, Lab Malalties Hepat, Internal Med, Barcelona, Spain
Roche Diagnost, Sant Cugat Del Valles, Spain
Esteban, JI:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
VHIR HUVH, Liver Unit, Lab Malalties Hepat, Internal Med, Barcelona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Ribera, E:
Univ Autonoma Barcelona, Barcelona, Spain
Hosp Univ Vall DHebron, Infect Dis Dept, Barcelona, Spain
Quer, J:
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
VHIR HUVH, Liver Unit, Lab Malalties Hepat, Internal Med, Barcelona, Spain
Puig, L:
Serv Catala Salut, Banc Sang & Teixits, Transfus Safety Lab, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
Sauleda, S:
Serv Catala Salut, Banc Sang & Teixits, Transfus Safety Lab, Barcelona, Spain
Ctr Invest Biomed Red Enfermedades Hepat & Digest, Madrid, Spain
|